Generics companies get green light for Lundbeck drug

The patent for Lundbeck's drug Northera has officially expired in the US, and no less than 12 companies have so far received approval from the US health authorities to market a generic version of the drug.

Photo: Jens Dresling

On Feb. 18, the patent for Lundbeck's Northera officially expired in the US, after which companies are lining up to bite into the market, which the Danish pharmaceutical giant has exclusive rights to up until now.

12 companies, including Teva's generics business and Indian Lupin, have received approvals for their respective copies of the product with the name droxidopa.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs